| Entry |
|
|---|
| Name |
Tadalafil (JAN/USAN/INN);
Adcirca (TN);
Cialis (TN);
Zalutia (TN)
|
|---|
| Product |
CIALIS (Aphena Pharma Solutions - Tennessee), ADCIRCA (Aphena Pharma Solutions - Tennessee), CIALIS (Aphena Pharma Solutions - Tennessee), CIALIS (Bryant Ranch Prepack), CIALIS (Bryant Ranch Prepack), CIALIS (Cardinal Health), CIALIS (Dispensing Solutions), CIALIS (Eli Lilly and Company), CIALIS (PD-Rx Pharmaceuticals), CIALIS (Rebel Distributors Corp.), CIALIS (Unit Dose Services), ADCIRCA (United Therapeutics Corporation) |
|---|
| Generic |
TADALAFIL (A-S Medication Solutions), TADALAFIL (A-S Medication Solutions), TADALAFIL (Accord Healthcare), TADALAFIL (Ajanta Pharma Limited), TADALAFIL (Ajanta Pharma Limited), TADALAFIL (Alembic Pharmaceuticals), TADALAFIL (Alembic Pharmaceuticals Limited), TADALAFIL (Amneal Pharmaceuticals NY LLC), TADALAFIL (Aphena Pharma Solutions - Tennessee), TADALAFIL (Apotex Corp.), TADALAFIL (Aurobindo Pharma Limited), TADALAFIL (Aurobindo Pharma Limited), TADALAFIL (AvKARE), ALYQ (AvKARE), TADALAFIL (Burel Pharma), TADALAFIL (Cadila Healthcare Limited), TADALAFIL (Camber Pharmaceuticals), TADALAFIL (Camber Pharmaceuticals), TADALAFIL (Cipla USA), TADALAFIL (Cipla USA), TADALAFIL (Dr.Reddys Laboratories), TADALAFIL (Dr.Reddys Laboratories), TADALAFIL (Lupin Pharmaceuticals), TADALAFIL (Lupin Pharmaceuticals), TADALAFIL (Mylan Pharmaceuticals), TADALFIL (Mylan Pharmaceuticals), TADALAFIL (Mylan Pharmaceuticals), TADALAFIL (PD-Rx Pharmaceuticals), TADALAFIL (Prasco Laboratories), TADALAFIL (Qilu Pharmaceutical), TADALAFIL (Sun Pharmaceutical Industries), TADALAFIL (Sunshine Lake Pharma), TADALAFIL (Teva Pharmaceuticals USA), ALYQ (Teva Pharmaceuticals USA), TADALAFIL (Torrent Pharmaceuticals Limited), TADALAFIL (Torrent Pharmaceuticals Limited), TADALAFIL (Unichem Pharmaceuticals (USA)), TADALAFIL (Unit Dose Services), TADALAFIL (Unit Dose Services), TADALAFIL (Zydus Pharmaceuticals (USA)) |
|---|
| Formula |
C22H19N3O4
|
|---|
| Exact mass |
389.1376
|
|---|
| Mol weight |
389.404
|
|---|
| Structure |
   |
|---|
| Class |
Cardiovascular agent
DG01509 Phosphodiesterase V inhibitor
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
|
|---|
| Efficacy |
Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor |
|---|
| Disease |
Pulmonary arterial hypertension [DS: H01621] |
|---|
| Comment |
Treatment of male erectile and female sexual dysfunction
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04B UROLOGICALS
G04BE Drugs used in erectile dysfunction
G04BE08 Tadalafil
D02008 Tadalafil (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Genitourinary Agents
Benign Prostatic Hypertrophy Agents
Tadalafil
D02008 Tadalafil (JAN/USAN/INN)
Respiratory Tract/Pulmonary Agents
Pulmonary Antihypertensives
Tadalafil
D02008 Tadalafil (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D02008 Tadalafil (JAN/USAN/INN)
25 Urogenital and anal organ agents
259 Miscellaneous
2590 Miscellaneous
D02008 Tadalafil (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE5
D02008 Tadalafil (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02008
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02008
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02008
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02008
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 29
1 N1y N 29.4582 -12.6733
2 C1x C 30.1741 -13.7777
3 C5x C 29.5963 -15.0632
4 N1y N 28.2326 -15.0448
5 C1y C 27.4708 -14.1585
6 C5x C 28.0566 -12.6389
7 C1y C 27.6549 -16.4236
8 C8y C 26.2912 -16.4518
9 C1x C 26.1152 -14.1159
10 C8y C 25.5294 -15.3555
11 O5x O 27.2788 -11.5908
12 O5x O 30.4201 -16.2432
13 C8y C 28.4706 -17.5343
14 C8x C 29.8722 -17.4755
15 C8x C 30.6960 -18.6089
16 C8y C 30.0724 -19.9725
17 C8y C 28.6250 -19.9694
18 C8x C 27.8471 -18.8281
19 O2x O 30.5829 -21.1851
20 C1x C 29.5192 -22.1306
21 O2x O 28.3012 -21.3988
22 C1a C 30.0900 -11.4256
23 C8y C 24.1928 -15.8284
24 C8y C 24.2058 -17.2380
25 N4x N 25.5595 -17.6699
26 C8x C 22.9827 -15.1426
27 C8x C 21.7866 -15.8747
28 C8x C 21.8003 -17.2924
29 C8x C 23.0561 -17.9701
BOND 34
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 4 7 1
8 7 8 1
9 5 9 1
10 10 8 2
11 9 10 1
12 6 11 2
13 3 12 2
14 7 13 1 #Down
15 13 14 2
16 14 15 1
17 15 16 2
18 16 17 1
19 17 18 2
20 13 18 1
21 16 19 1
22 19 20 1
23 20 21 1
24 17 21 1
25 1 22 1
26 10 23 1
27 23 24 1
28 24 25 1
29 25 8 1
30 23 26 2
31 26 27 1
32 27 28 2
33 28 29 1
34 24 29 2
|
|---|
|
